
|Videos|September 16, 2011
Dr. Rugo on VEGF-A as an Avastin Response Predictor
Author(s)Hope S. Rugo, MD
Dr. Hope Rugo from UCSF Cancer Center on VEGF-A as an Avastin Response Predictor
Advertisement
Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, University of California, San Francisco, discusses the AVADO trial that investigated VEGF levels as a predictor of response to antiangiogenesis agents, particularly bevacizumab (Avastin).
A retrospective analysis of the data present by David W. Miles, MD, suggested that if VEGF-A levels were divided into quartiles the highest quartet level predicted higher response rates to bevacizumab.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































